Hiperplaziile endometrului şi aspectele tratamentului hormonal local.

Sofroni Dumitru; Balan Roman; Ancuţa Eugen; Ciornii A.; Tripac-Iacovleva Irina; Guţu Lilian; Ciobanu Veronica; Rosca Sergiu; Eşanu Nicolae

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

826

Ultima descărcare din IBN:
2022-01-30 22:45

Căutarea după subiecte
similare conform CZU

618.14-006.55-085:616-095 (1)

Științe medicale. Medicină (11136)

Patologie. Medicină clinică (6963)

SM ISO690:2012

SOFRONI, Dumitru, BALAN, Roman, ANCUŢA, Eugen, CIORNII, A., TRIPAC-IACOVLEVA, Irina, GUŢU, Lilian, CIOBANU, Veronica, ROSCA, Sergiu, EŞANU, Nicolae. Hiperplaziile endometrului şi aspectele tratamentului hormonal local.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2018, nr. 2-3(59-60), pp. 45-50. ISSN 1857-0011.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale

Numărul 2-3(59-60) / 2018 / ISSN 1857-0011

Hiperplaziile endometrului şi aspectele tratamentului hormonal local.

Endometrial hyperplasia and two pathogenic types of endometrial cancer and treatment aspects.

Гиперплазия эндометрия и рак эндометрия два патогенные и лечения вопросы.

CZU: 618.14-006.55-085:616-095

Pag. 45-50

Sofroni Dumitru, Balan Roman, Ancuţa Eugen, Ciornii A., Tripac-Iacovleva Irina, Guţu Lilian, Ciobanu Veronica, Rosca Sergiu, Eşanu Nicolae

IMSP Institutul Oncologic

Disponibil în IBN: 4 ianuarie 2019

Descarcă PDF

Rezumat

Cancerele endometrale se întâlnesc cu aceeaşi frecventă maximală în două decade: perioada 50-59 ani, care poate fi numită perimenopauzală, şi perioada 60-69 ani, cea postmenopauzală. Cancerul perimenopauzal, cum mărturisesc datele obţinute, poate avea ca precursori hiperplaziile endometrale, îndeosebi cele atipice, foarte frecvent însoţite de manifestări clinice dishormonale. Al doilea tip de cancer endometral, cel postmenopauzal, poate avea ca precursor numai hiperplaziile atipice care mai persistă în această perioadă, sau se dezvoltă intru-un endometru aparent atrofic. Tratamentul hormonal local cu relizing sistem „Mirena” poate fi apreciat ca o alternativă efectivă a tratamentului conservativ sistemic hormonal a stărilor precursore a cancerului endometrial, ce permite a exclude efectele secundare negative specifice pentru tratament cu progestine prolangate şi cu agonişti de relizing factori, folosite până în prezent.

Endometrial cancers maximum meet with the same frequency in two decades: between 50-59 years, which may be called perimenopause, and between 60-69 years, the postmenopausal. Perimenopause cancer, as data obtained, endometrial hyperplasia may precursors, particularly atypical, very often accompanied by clinical dishormonal manifestations. The second type of endometrial cancer, the postmenopausal, could have only precursor atypical hyperplasia persisting in this period. Hormonal therapy with relizing local system “Mirena” can be considered as an alternative to conservative treatment effective systemic hormonal states of endometrial cancer precursors, which allows to exclude the negative side effects to treatment with specific agonists and progestins prolangate relizing factors used at present.

Раки эндометрия встречаются с той же частотой в двух десятилетиях: между 50-59 лет, который может быть назван перименопаузой, а также между 60-69 лет, в постменопаузе. Перименопаузальный рак, как показывают полученные данные, может иметь такие предшественники, как, гиперплазия эндометрия, особенно атипическая, очень часто сопровождается клиническими дисгормональными проявлениями. Второй тип рака эндометрия, в постменопаузе, может иметь только один предшественник атипическую гиперплазию сохраняющуюся в этот период. Местная гормональная терапия с системой «Мирена» можно рассматривать как альтернативу консервативного лечения предшественников рака, что позволяет исключить негативные побочные эффекты.

Cuvinte-cheie
hiperplaziile endometriului, tratament hormonal local., cancer endometrial

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-70200</cfResPublId>
<cfResPublDate>2018-12-25</cfResPublDate>
<cfVol>59-60</cfVol>
<cfIssue>2-3</cfIssue>
<cfStartPage>45</cfStartPage>
<cfISSN>1857-0011</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/70200</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Hiperplaziile endometrului şi aspectele tratamentului hormonal local.</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>hiperplaziile endometriului; tratament hormonal local.; cancer endometrial</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Cancerele endometrale se &icirc;nt&acirc;lnesc cu aceeaşi frecventă maximală &icirc;n două decade: perioada 50-59 ani, care poate fi numită perimenopauzală, şi perioada 60-69 ani, cea postmenopauzală. Cancerul perimenopauzal, cum mărturisesc datele obţinute, poate avea ca precursori hiperplaziile endometrale, &icirc;ndeosebi cele atipice, foarte frecvent &icirc;nsoţite de manifestări clinice dishormonale. Al doilea tip de cancer endometral, cel postmenopauzal, poate avea ca precursor numai hiperplaziile atipice care mai persistă &icirc;n această perioadă, sau se dezvoltă intru-un endometru aparent atrofic. Tratamentul hormonal local cu relizing sistem &bdquo;Mirena&rdquo; poate fi apreciat ca o alternativă efectivă a tratamentului conservativ sistemic hormonal a stărilor precursore a cancerului endometrial, ce permite a exclude efectele secundare negative specifice pentru tratament cu progestine prolangate şi cu agonişti de relizing factori, folosite p&acirc;nă &icirc;n prezent.</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Endometrial cancers maximum meet with the same frequency in two decades: between 50-59 years, which may be called perimenopause, and between 60-69 years, the postmenopausal. Perimenopause cancer, as data obtained, endometrial hyperplasia may precursors, particularly atypical, very often accompanied by clinical dishormonal manifestations. The second type of endometrial cancer, the postmenopausal, could have only precursor atypical hyperplasia persisting in this period. Hormonal therapy with relizing local system &ldquo;Mirena&rdquo; can be considered as an alternative to conservative treatment effective systemic hormonal states of endometrial cancer precursors, which allows to exclude the negative side effects to treatment with specific agonists and progestins prolangate relizing factors used at present. &nbsp;&nbsp;</p></cfAbstr>
<cfAbstr cfLangCode='RU' cfTrans='o'><p>Раки эндометрия встречаются с той же частотой в двух десятилетиях: между 50-59 лет, который может быть назван перименопаузой, а также между 60-69 лет, в постменопаузе. Перименопаузальный рак, как показывают полученные данные, может иметь такие предшественники, как, гиперплазия эндометрия, особенно атипическая, очень часто сопровождается клиническими дисгормональными проявлениями. Второй тип рака эндометрия, в постменопаузе, может иметь только один предшественник атипическую гиперплазию сохраняющуюся в этот период. Местная гормональная терапия с системой &laquo;Мирена&raquo; можно рассматривать как альтернативу консервативного лечения предшественников рака, что позволяет исключить негативные побочные эффекты.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-170</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10655</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-40559</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29260</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-16033</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11123</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10979</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-17579</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-1238</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-170</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-170-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Софрони</cfFamilyNames>
<cfFirstNames>Думитру</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10655</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10655-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Балан</cfFamilyNames>
<cfFirstNames>Р.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-40559</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-40559-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Ancuţa</cfFamilyNames>
<cfFirstNames>Eugen</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29260</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29260-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Ciornii</cfFamilyNames>
<cfFirstNames>A.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-16033</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-16033-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Tripac-Iacovleva</cfFamilyNames>
<cfFirstNames>Irina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11123</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11123-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Guţu</cfFamilyNames>
<cfFirstNames>Lilian</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10979</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10979-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Ciobanu</cfFamilyNames>
<cfFirstNames>Veronica</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-17579</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-17579-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Рошка</cfFamilyNames>
<cfFirstNames>С.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-1238</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-1238-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Eshanu</cfFamilyNames>
<cfFirstNames>N.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>